This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia


Schmidt, Reinhold, Alf, Claude, Bancher, Christian, Benke, Thomas, Berek, Klaus, Dal-Bianco, Peter, Führwürth, Gerhard, Imarhiagbe, Douglas, Jagsch, Christian, Lechner, Anita, Rainer, Michael, Reisecker, Franz, Rotaru, Juliana, Uranüs, Margarete, Walter, Andreas, Winkler, Andreas, Wuschitz, Albert


Neuropsychiatrie: Klinik, Diagnostik, Therapie Und Rehabilitation: Organ Der Gesellschaft Österreichischer Nervenärzte Und Psychiater, Volume: 23, No.: 1, Pages.: 58-63

Year of Publication



We performed a 6-month open-label study on the use of the transdermal rivastigmine patch in clinical routine in 103 patients with Alzheimer’s disease from 25 outpatient services in Austria. After baseline, safety and tolerability of the 10 cm2–rivastigmine patch was assessed at week 4, 12 and 24 in all patients. A Mini Mental State Examination was done at baseline and at week 12 and 24. Skin adherence of the patch was very good or good in 85% of study participants. Only 2.9% of patients had gastrointestinal adverse events. Local skin reactions occurred in 23% of individuals. Skin alteration were mostly mild in severity. In only 6.8% of subjects did they result in termination of treatment. At the earliest skin reactions were observed after 3 months of treatment. Cognitive functioning of patients improved comparable to the controlled trial which led to approval of the rivastigmine patch. In daily routine the safety profile of the rivastigmine patch is favourable, as is the response to treatment. Local, mostly mild skin reactions affect approximately every fifth patient, and they occur relatively late in the course of therapy. Patients and their caregivers should receive detailed information about skin reactions to omit unnecessary drop outs to treatment.;


administration & dosage, administration cutaneous, adverse, adverse effects, aged, aged, 80 and over, alzheimer disease, cholinesterase inhibitors, drug therapy, events, female, humans, male, mental status schedule, patch, phenylcarbamates, rivastigmine, transdermal, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Before and After Study

Type of Outcomes

Cognition, Other


Hospital Outpatient Care

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime